Explore Stanford technologies available for licensing:

Stanford researchers have developed a targeted therapy for Alzheimer's disease that focuses on inhibiting the spread of tau protein, a key factor in disease progression.

Stanford researchers have developed AZD7648, a novel DNA-PK inhibitor that enhances HDR efficiency in CRISPR-Cas9 gene editing by shifting DNA repair from the error-prone NHEJ pathway to the precise HDR pathway, significantly improving gene targeting outcomes in human cells fo

Type 1 regulatory T cells (Tr1s) are an inducible subtype of regulatory T cells that can play a beneficial (autoimmune diseases, allergy, hematological malignancies) or detrimental role (some solid tumors and infectious diseases) in human diseases. Tr1 cells.

The coronavirus main protease (Mpro), which is a trypsin-like protease with a catalytic cysteine residue, processes viral proteins in an early step of the coronavirus life cycle, and its activity is required for viral replication.

A new deep-learning system called Atomic Rotationally Equivariant Scorer (ARES) significantly improves the prediction of RNA structures over previous artificial intelligence (AI) models.

Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.

Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.

The Longaker lab at Stanford University has developed a machine learning algorithm that can analyze and detect fibrotic disease.

A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.

Stanford inventors have developed a method of using human induced pluripotent stem (hiPS) cells to generate three-dimensional neural floorplate organizers that are functionally active and capable of choreographing midline brain development.

Scientists in the Sunwoo Lab at Stanford have discovered that inhibition of the histone lysine demethylase KDMA2 can enhance the efficacy of immune checkpoint blockade therapies, like anti-PD-1.

Researchers at Stanford have identified the use of the drug verteporfin to treat or reduce the risk of developing ibrosis after ocular procedures or ocular injury. Of interest is corneal injury, for example after refractive surgery or crosslinking, e.g.

Researchers at Stanford have developed innovative Verteporfin conjugates that considerably enhance the solubility and therapeutic potential of Verteporfin.

Researchers at Stanford have proposed that coating surgical sutures with mechanotransduction inhibitors may reduce scarring of the tissue.

Researchers at Stanford University have discovered a novel way of treating dry age-related macular degeneration by inhibiting a causal disease target.